Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant
Open Access
- 1 January 2018
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 5 (1) , ofx258
Abstract
We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed in 2002, 2009, and 2015. The study was performed in 43 centers during October–November 2016. The sample was estimated for an accuracy of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV transmissibility. The reference population and the sample size were 38904 and 1588 patients, respectively. The prevalence of HCV-Abs in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend <.001, from 2002 to 2015). The prevalence of active HCV in 2002, 2009, 2015, and 2016 was 54.0%, 34.0%, 22.1%, and 11.7%, respectively (P trend <.001). The anti-HCV treatment uptake in 2002, 2009, 2015, and 2016 was 23.0%, 48.0%, 59.3%, and 74.7%, respectively (P trend <.001). In 2016, HCV-related cirrhosis was present in 7.6% of all HIV-infected individuals, 15.0% of patients with active HCV, and 31.5% of patients who cleared HCV after anti-HCV therapy. Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden of HCV-related cirrhosis will continue to be significant among HIV-infected individuals.Keywords
Funding Information
- Gilead Fellowship Programme
- Spanish AIDS Research Network (RD16/0025/0017, RD16/0025/0018)
This publication has 22 references indexed in Scilit:
- Lack of decline in hepatitis C virus incidence among HIV-positive men who have sex with men during 1990–2014Journal of Hepatology, 2017
- Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient CharacteristicsOpen Forum Infectious Diseases, 2016
- Risk Factors for Sexual Transmission of Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men: A Case-Control StudyOpen Forum Infectious Diseases, 2015
- Therapy of Hepatitis C — Back to the FutureNew England Journal of Medicine, 2014
- An Epidemiologic Update on Hepatitis C Infection in Persons Living With or at Risk of HIV InfectionThe Journal of Infectious Diseases, 2013
- Acute Hepatitis C in Patients with HIVSeminars in Liver Disease, 2012
- Non-invasive evaluation of liver fibrosis using transient elastographyJournal of Hepatology, 2008
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- Estudio multicéntrico sobre prevalencia de las coinfecciones por virus de hepatitis, indicación de tratamiento de hepatitis crónica C y necesidad de trasplante hepático en pacientes infectados por el VIH en España. Estudio GESIDA 29/02-FIPSE 12185/01Enfermedades Infecciosas y Microbiología Clínica, 2005
- Hepatitis C Virus Infection as an Opportunistic Disease in Persons Infected with Human Immunodeficiency VirusClinical Infectious Diseases, 2000